Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Diabetes and cancer in the age of multimorbidity
[1] These effects typically diminish over time as patients develop tolerance, usually within the first few weeks of therapy
Intrapatient changes in CT-based body composition after initiation of semaglutide (glucagon-like peptide-1 agonist) therapy
Hepatic glucagon increases gluconeogenesis and lipolysis via PKA/CREB activation, stimulates brown adipose tissue thermogenesis, and reduces hepatic triglyceride accumulation
US$ 27.51
US$ 27.06
US$ 29.76
